TY - JOUR
T1 - Kawasaki Disease Arab Initiative [Kawarabi]
T2 - Establishment and Results of a Multicenter Survey
AU - Arab, Yousra
AU - Choueiter, Nadine
AU - Dahdah, Nagib
AU - El-Kholy, Nermeen
AU - Abu Al-Saoud, Sima Y.
AU - Abu-Shukair, Mohammed E.
AU - Agha, Hala M.
AU - Al-Saloos, Hesham
AU - Al Senaidi, Khalfan Salim
AU - Alzyoud, Raed
AU - Bouaziz, Asma
AU - Boukari, Rachida
AU - El Ganzoury, Mona M.
AU - Elmarsafawy, Hala M.
AU - ELrugige, Najat
AU - Fitouri, Zohra
AU - Ladj, Mohamed S.
AU - Mouawad, Pierre
AU - Salih, Aso F.
AU - Rojas, Rocio G.
AU - Harahsheh, Ashraf S.
N1 - Funding Information:
Fonds BoBeau Coeur, Division of Pediatric Cardiology, CHU Sainte-Justine. Dr. Harahsheh is supported by a Sub-agreement from the Johns Hopkins University with funds provided by Grant No. R61HD105591 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Office of the Director, National Institute of Health (OD). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development, the Office of the Director, National Institute of Health (OD), the National Institute of Health, the NIBIB, the NHLBI, or the Johns Hopkins University. Non-financial interest: Dr. Harahsheh serves as a scientific advisory board member of OP2 DRUGS (“OP2”). This advisory position has no relevant disclosures for this manuscript.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/8
Y1 - 2022/8
N2 - Studies on Kawasaki disease (KD) in Arab countries are scarce, often providing incomplete data. This along with the benefits of multicenter research collaboratives led to the creation of the KD Arab Initiative [Kawarabi] consortium. An anonymous survey was completed among potential collaborative Arab medical institutions to assess burden of KD in those countries and resources available to physicians. An online 32-item survey was distributed to participating institutions after conducting face validity. One survey per institution was collected. Nineteen physicians from 12 countries completed the survey representing 19 out of 20 institutions (response rate of 95%). Fifteen (79%) institutions referred to the 2017 American Heart Association guidelines when managing a patient with KD. Intravenous immunoglobulin (IVIG) is not readily available at 2 institutions (11%) yet available in the country. In one center (5%), IVIG is imported on-demand. The knowledge and awareness among countries’ general population was graded (0 to 10) at median/interquartiles (IQR) 3 (2–5) and at median/IQR 7 (6–8) in the medical community outside their institution. Practice variations in KD management and treatment across Arab countries require solid proactive collaboration. The low awareness and knowledge estimates about KD among the general population contrasted with a high level among the medical community. The Kawarabi collaborative will offer a platform to assess disease burden of KD, among Arab population, decrease practice variation and foster population-based knowledge.
AB - Studies on Kawasaki disease (KD) in Arab countries are scarce, often providing incomplete data. This along with the benefits of multicenter research collaboratives led to the creation of the KD Arab Initiative [Kawarabi] consortium. An anonymous survey was completed among potential collaborative Arab medical institutions to assess burden of KD in those countries and resources available to physicians. An online 32-item survey was distributed to participating institutions after conducting face validity. One survey per institution was collected. Nineteen physicians from 12 countries completed the survey representing 19 out of 20 institutions (response rate of 95%). Fifteen (79%) institutions referred to the 2017 American Heart Association guidelines when managing a patient with KD. Intravenous immunoglobulin (IVIG) is not readily available at 2 institutions (11%) yet available in the country. In one center (5%), IVIG is imported on-demand. The knowledge and awareness among countries’ general population was graded (0 to 10) at median/interquartiles (IQR) 3 (2–5) and at median/IQR 7 (6–8) in the medical community outside their institution. Practice variations in KD management and treatment across Arab countries require solid proactive collaboration. The low awareness and knowledge estimates about KD among the general population contrasted with a high level among the medical community. The Kawarabi collaborative will offer a platform to assess disease burden of KD, among Arab population, decrease practice variation and foster population-based knowledge.
KW - Arab
KW - Cardiac complications
KW - Kawasaki disease
KW - Multicenter collaborative
KW - Registry
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=85130725641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130725641&partnerID=8YFLogxK
U2 - 10.1007/s00246-022-02844-w
DO - 10.1007/s00246-022-02844-w
M3 - Article
C2 - 35624313
AN - SCOPUS:85130725641
SN - 0172-0643
VL - 43
SP - 1239
EP - 1246
JO - Pediatric Cardiology
JF - Pediatric Cardiology
IS - 6
ER -